ReviewApoptosis : an international journal on programmed cell death2026
Looking at the fraction with Annexin V⁺ and propidium iodide⁺: insights into cell death types from preclinical studies in solid and haematological cancers.
Review in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Green Fabrication and Characterization of Copper Oxide Nanoparticles Using C. Gigantea Leaf Extract and Their ROS-Mediated Anticancer Activity Against A549 Lung Cancer Cells.Cell biochemistry and biophysics · 2026Article
- Therapeutic Potential ofInternational journal of molecular sciences · 2026Article
- Ribosome-Inactivating Proteins fromBiomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluorescein isothiocyanate-conjugated Annexin V in combination with propidium iodide (PI) labelling is a widely used flow cytometric assay for quantifying apoptotic and necrotic cells in anticancer studies. However, increasing evidence suggests that double-positive cells, or the Annexin V⁺/PI⁺ fraction, may represent not only late apoptosis but also different modalities of regulated cell death, including necroptosis, pyroptosis, ferroptosis, and cuproptosis. By collating findings from preclinical studies across different cancer cells, this review highlights the need for consensus in interpreting Annexin V⁺/PI⁺ populations. In the absence of molecular and/or microscopy data, this fraction is more appropriately classified as undergoing 'late-stage cell death'. In short, establishing standardised interpretive criteria is crucial to enhance understanding, facilitate cross-study comparability, and improve the translational relevance of anticancer research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.